>美国和欧洲软骨再生市场，按类型（透明软骨、纤维软骨和弹性软骨）、治疗方式（基于细胞和非基于细胞）、治疗类型（内在修复刺激和姑息治疗）、应用部位（膝关节、髋关节、踝关节、脊柱等）、外科手术程序（骨软骨移植、自体软骨细胞植入、基质自体软骨植入 (MACI)、软骨成形术和微骨折、截骨术、关节镜检查、磨损关节成形术、幼年同种异体移植碎片等）、最终用户（医院和诊所、学术和研究机构、门诊手术中心、矫正中心等）划分 - 行业趋势和预测到 2031 年。
美国和欧洲软骨再生市场分析及规模
推动市场增长的主要因素之一是骨关节炎患病率的上升。此外，研发活动投资的增加是推动市场增长的另一个关键因素。政府推动先进医疗基础设施的举措也影响着市场。然而，缺乏熟练的专业人员以及骨科植入物和手术的高昂成本正在制约市场的增长。
Data Bridge Market Research 分析，美国和欧洲软骨再生市场预计将从 2023 年的 590,964.54 万美元达到 2031 年的 1,474,396.99 万美元的价值，在 2024 年至 2031 年的预测期内以 12.8% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2024 至 2031 年 |
|
基准年 |
2023 |
|
历史岁月 |
2022 (可定制为 2016-2021) |
|
定量单位 |
收入（千美元） |
|
涵盖的领域 |
类型（透明软骨、纤维软骨和弹性软骨）、治疗方式（基于细胞和非基于细胞）、治疗类型（内在修复刺激和姑息治疗）、应用部位（膝关节、髋关节、踝关节、脊柱等）、手术程序（骨软骨移植、自体软骨细胞植入、基质自体软骨植入 (MACI)、软骨成形术和微骨折、截骨术、关节镜检查、磨损关节成形术、幼年同种异体移植碎片等）、最终用户（医院和诊所、学术和研究机构、门诊手术中心、矫正中心等） |
|
覆盖国家 |
美国、德国、英国、法国、意大利、西班牙、俄罗斯、波兰、瑞士、荷兰、土耳其、瑞典、比利时、丹麦、芬兰、挪威和欧洲其他地区 |
|
涵盖的市场参与者 |
Zimmer Biomet、Vericel Corporation.、Arthrex, Inc.、CONMED Corporation.、RTI Surgical、Smith+Nephew.、Anika Therapeutics, Inc.、Geistlich Pharma AG、AlloSource、TETEC AG (B. Braun SE 的子公司)、meidrix biomedicals GmbH.、Bioinova、as、Lamina Therapeutics、CO.DON、Novartis AG、Cartilage Inc. 和 Histogen Inc. 等 |
市场定义
软骨再生是指开发和应用医疗技术和疗法来修复人体受损或退化的软骨组织。软骨是一种结缔组织，在支撑和缓冲关节方面起着至关重要的作用，其损伤可能是由受伤、关节炎或其他退行性疾病造成的。
美国和欧洲软骨再生市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 骨关节炎患病率上升
骨关节炎在老年人中更为常见，随着老龄人口的增加，这种疾病的发病率也更高。由于衰老，关节更容易患骨关节炎。因此，老年人口代表着软骨再生疗法的巨大市场。肥胖是骨关节炎的一个已知风险因素，特别是在膝盖和臀部等负重关节中。全球肥胖率的上升导致骨关节炎发病率上升，尤其是在年轻群体中。肥胖者的关节压力往往更大，从而加速软骨退化，并产生对再生解决方案的需求。
骨关节炎患病率的上升是推动软骨再生市场增长的重要因素。随着区域人口老龄化和骨关节炎风险因素的持续存在，对解决软骨损伤的先进再生解决方案的需求预计将继续增长。市场可能会看到进一步的进步、研究和创新，以满足与骨关节炎相关的不断增长的医疗保健需求。
- 研发活动投资不断增加
增加研发投入促进了再生医学先进技术的探索和发展。干细胞治疗、组织工程和 3D 生物打印等技术不断发展，为软骨再生提供更有效、更精确的解决方案。研发活动带来了专为软骨再生设计的新产品。制药公司和生物技术公司投资开发新药、生物制剂和医疗器械，以解决软骨修复的复杂性并促进更好的患者治疗效果。
大量的研发投入使得临床试验得以启动和推进。这些试验对于评估新型软骨再生疗法的安全性和有效性至关重要。积极的试验结果有助于获得监管部门的批准并最终实现这些治疗方法的商业化。研发工作有助于更深入地了解软骨退化和再生机制。这些知识对于开发针对性和个性化的疗法至关重要，这些疗法可以满足不同程度软骨损伤患者的特定需求。
研发活动投资的不断增加推动了市场的增长，促进了创新、改善了治疗方式、提高了科学理解，并最终为软骨相关疾病患者带来了新的有效解决方案。这些投资促进了市场的发展，使其成为再生医学领域中一个充满活力且反应迅速的领域，从而推动了市场的增长。
机会
- 增加对微创手术的需求
微创手术（或微创外科手术）包括限制所需切口大小的外科技术，从而减少伤口愈合时间、相关疼痛和感染风险。从定义上讲，外科手术是侵入性的，许多需要一定大小切口的手术被称为开放手术。微创手术包括关节置换、运动损伤的关节镜修复以及复杂肌肉骨骼疾病的微观治疗。它包括恢复时间短、感染风险低、出血少、疤痕小和住院时间短。
MIS 中使用的技术和仪器（例如导航辅助手术设备）对身体的损伤比开放式手术要小。微创手术技术不断进步，可用于对各种残疾患者进行手术，预计将推动软骨再生市场的增长。
通过先进技术进行的微创手术具有巨大的优势。微创手术需求的不断增长预计将为市场带来增长机会。
克制/挑战
- 软骨再生的报销情况不佳
软骨再生疗法通常涉及先进和创新的技术，这些技术可能很昂贵。在报销情况不佳的情况下，患者可能面临更高的自付费用，从而限制了他们负担这些治疗的能力。这种经济障碍可能会阻止患者选择软骨再生手术，从而减少市场需求。当报销政策足以支付费用时，医生和医疗保健提供者更有可能采用和推荐软骨再生疗法。报销情况不佳可能会导致医疗保健专业人员不愿提供这些治疗，因为他们可能担心对患者及其实践的财务影响。
在竞争激烈的医疗保健行业，报销政策可以显著影响市场动态。如果软骨再生疗法的报销有限或不一致，则可能会阻碍这些治疗与传统或替代干预措施相比的竞争力。这反过来又限制了市场的增长潜力。
软骨再生技术的采用速度可能较慢，在没有强有力的报销支持的情况下，限制了它们融入主流医疗实践。这反过来又限制了市场扩张及其在治疗骨科疾病和伤害方面的全部潜力的发挥。
最新动态
- 2023 年 5 月，加州大学欧文分校的生物医学初创公司 Cartilage Inc. 正在开发一种产品，该产品将通过再生缺失组织和修复下颌关节缺陷来恢复颞下颌关节功能。这有助于该公司加强其产品组合
- 2021 年 9 月，诺华公司宣布美国食品药品监督管理局 (FDA) 已授予 LNA043 治疗膝骨关节炎的快速通道资格。这有助于该公司在骨关节炎产品领域确立地位
- 2020 年 9 月，Lamina Therapeutics 宣布其依靠斯特拉斯堡科学团队的研究工作，该团队由 INSERM UMR 1260 / RNM（再生纳米医学）部门主任、LAMINA THERAPEUTICS 创始成员 Nadia JESSEL 教授协调。这项创新技术旨在开发用于再生医学的新一代联合先进治疗药物产品 (cATMP)，特别是用于重建骨骼、软骨和骨软骨单元
- 2021 年 1 月，运动医学和严重烧伤护理市场先进疗法领域的领导者 Vericel Corporation 宣布，联合健康保险已扩大其 MACI（猪胶原膜上自体培养的软骨细胞）医疗政策，将覆盖范围扩大到髌骨全层软骨缺损和膝关节多发性软骨缺损患者
- 2020 年 10 月，Cartilage Inc. 获得了美国国立卫生研究院 (NIH) 颁发的 252,000 美元第一阶段小企业创新研究 (SBIR) 资助。这家初创公司利用这笔资助研究其产品 Hyaleon 的可行性，Hyaleon 是一种无支架、组织工程软骨植入物，能够愈合
美国和欧洲软骨再生市场范围
美国和欧洲的软骨再生市场分为六个显著的细分市场，例如类型、治疗方式、治疗类型、应用部位、手术程序和最终用户。这些细分市场之间的增长将帮助您分析行业中微弱的增长细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，以确定核心市场应用。
类型
- 透明软骨
- 纤维软骨
- 弹性软骨
根据类型，美国和欧洲的软骨再生市场分为透明软骨、纤维软骨和弹性软骨。
治疗方式
- 基于细胞
- 非基于细胞
根据治疗方式，美国和欧洲的软骨再生市场分为基于细胞的和非基于细胞的。
治疗类型
- 内在修复刺激
- 姑息治疗
根据治疗类型，美国和欧洲的软骨再生市场分为内在修复刺激治疗和姑息治疗。
申请地点
- 膝盖
- 时髦的
- 踝
- 脊柱
- 其他的
根据应用部位，美国和欧洲的软骨再生市场分为膝盖、臀部、脚踝、脊柱和其他。
手术程序
- 骨软骨移植
- 自体软骨细胞移植
- 基质自体软骨植入 (MACI)
- 软骨成形术和微骨折
- 截骨术
- 关节镜检查
- 磨损关节置换术
- 幼年同种异体移植碎片
- 其他的
根据手术程序，美国和欧洲的软骨再生市场细分为骨软骨移植、自体软骨细胞植入、基质自体软骨植入 (MACI)、软骨成形术和微骨折、截骨术、关节镜检查、磨削关节成形术、幼年同种异体移植碎片等。
最终用户
- 医院和诊所
- 学术及研究机构
- 门诊手术中心
- 垂心
- 其他的
根据最终用户，美国和欧洲软骨再生市场分为医院和诊所、学术和研究机构、门诊手术中心、矫形中心和其他。
美国和欧洲软骨再生市场区域分析/见解
对美国和欧洲的软骨再生市场进行了分析，并按国家、类型、治疗方式、治疗类型、应用部位、手术程序和最终用户提供了市场规模洞察和趋势。
本市场报告涵盖的国家包括美国、德国、英国、法国、意大利、西班牙、俄罗斯、波兰、瑞士、荷兰、土耳其、瑞典、比利时、丹麦、芬兰、挪威和欧洲其他地区。
由于各制造商的投资水平较高且对医药产品制造的需求不断增加，预计美国将主导美国和欧洲软骨再生市场。由于对研发活动的投资不断增加，预计德国将主导欧洲软骨再生市场。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了区域品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。
美国和欧洲软骨再生市场：竞争格局和份额分析
美国和欧洲软骨再生市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、新市场计划、区域存在、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
在美国和欧洲软骨再生市场运营的一些主要市场参与者包括 Zimmer Biomet、Vericel Corporation.、Arthrex, Inc.、CONMED Corporation、RTI Surgical、Smith+Nephew.、Anika Therapeutics, Inc. 和 Geistlich Pharma AG 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE U.S. & EU CARTILAGE REGENERATION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PSETEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 NUMBER OF PROCEDURES PERFORMED PER YEAR: BY COUNTRY
6 REGULATIONS
6.1 EUROPE CARTILAGE REGENERATION MARKET: REGULATIONS
6.1.1 CONFORMITY
6.1.2 CLINICAL INVESTIGATION
6.2 U.S. CARTLAGE REPAIRING MARKET: REGULATIONS
6.2.1 FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (CDRH)
6.2.2 FDA CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER)
6.2.3 CLINICAL TRIALS OVERSIGHT
6.2.4 POST-MARKET SURVEILLANCE
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF OSTEOARTHRITIS
7.1.2 RISING INVESTMENTS IN RESEARCH AND DEVELOPMENT ACTIVITIES
7.1.3 RISING HEALTHCARE EXPENDITURE TO PROMOTE CARTILAGE REGENERATION TREATMENT
7.1.4 INCREASING NUMBER OF JOINT INJURIES
7.2 RESTRAINTS
7.2.1 POOR REIMBURSEMENT SCENARIO FOR CARTILAGE REGENERATION
7.2.2 STRINGENT REGULATIONS FOR THE APPROVAL OF CARTILAGE REGENERATION PRODUCTS
7.3 OPPORTUNITIES
7.3.1 INCREASE DEMAND FOR MINIMALLY INVASIVE PROCEDURES
7.3.2 RISING TECHNOLOGICAL ADVANCEMENTS IN THE CARTILAGE REGENERATION PROCESS.
7.3.3 RISING AWARENESS OF MEDICAL TREATMENT IN EUROPE
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS IN HEALTHCARE MARKET
7.4.2 HIGH COST OF ORTHOPEDIC IMPLANTS AND SURGERIES
8 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TYPE
8.1 OVERVIEW
8.2 HYALINE CARTILAGE
8.3 FIBRO CARTILAGE
8.3.1 INTRA-ARTICULAR FIBROCARTILAGE
8.3.2 STRATIFORM FIBROCARTILAGE
8.3.3 CIRCUMFERENTIAL FIBROCARTILAGE
8.3.4 CONNECTING FIBROCARTILAGE
8.4 ELASTIC CARTILAGE
9 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY
9.1 OVERVIEW
9.2 CELL-BASED
9.2.1 CHONDROCYTE TRANSPLANTATION
9.2.1.1 AUTOLOGOUS CHONDROCYTE IMPLANTATION (ACI)
9.2.1.2 MATRIX-INDUCED AUTOLOGOUS CHONDROCYTE IMPLANTATION (MACI)
9.2.2 STEM CELLS
9.2.2.1 MESENCHYMAL STEM CELLS (MSC'S)
9.2.2.2 UMBILICAL CORD-DERIVED STEM CELL THERAPY
9.2.2.3 EMBRYONIC STEM CELL THERAPY
9.2.2.4 OTHERS
9.2.3 GROWTH FACTOR
9.2.3.1 PLATELET-RICH PLASMA (PRP)
9.2.3.2 AUTOLOGOUS CONDITIONED SERUM (ACS)
9.2.3.3 BONE MORPHOGENETIC PROTEIN (BMP) PRODUCTS
9.2.3.4 FIBROBLAST GROWTH FACTOR (FGF) PRODUCTS
9.2.3.5 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) PRODUCTS
9.2.3.6 OTHERS
9.2.4 OTHERS
9.3 NON - CELL BASED
9.3.1 SCAFFOLDS
9.3.1.1 NATURAL
9.3.1.1.1 HYALURONIC ACID (HA) PRODUCTS
9.3.1.1.2 COLLAGEN-BASED SCAFFOLDS
9.3.1.1.3 CHITOSAN SCAFFOLDS
9.3.1.1.4 DECELLULARIZED EXTRACELLULAR MATRIX
9.3.1.1.5 OTHERS
9.3.1.2 SYNTHETIC
9.3.1.2.1 POLY (LACTIC-CO-GLYCOLIC ACID) (PLGA) SCAFFOLDS
9.3.1.2.2 POLYETHYLENE GLYCOL (PEG) HYDROGELS:
9.3.1.2.3 OTHERS
9.3.2 CELL-FREE COMPOSITES
9.3.2.1 ARTIFICIAL CARTILAGE IMPLANT
9.3.2.2 OTHERS
10 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE
10.1 OVERVIEW
10.2 INTRINSIC REPAIR STIMULUS
10.3 PALLIATIVE
10.3.1 DEBRIDEMENT & LAVAGE
10.3.2 VISCOSUPPLEMENTATION
11 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE
11.1 OVERVIEW
11.2 KNEE
11.2.1 OSTEOCHONDRIAL GRAFTS TRANSPLANTATION
11.2.2 AUTOLOGOUS CHONDROCYTE
11.2.3 ARTHROSCOPIC CHONDROPLASTY
11.2.4 MICROFRACTURE
11.2.5 CELL-BASED CARTILAGE RESURFACING
11.2.6 OTHERS
11.3 HIP
11.4 ANKLE
11.5 SPINE
11.6 OTHERS
12 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURES
12.1 OVERVIEW
12.2 OSTEOCHONDRIAL TRANSPLANTATION
12.2.1 OSTEOCHONDRIAL AUTOGRAFT TRANSPLANTATION
12.2.2 OSTEOCHONDRIAL ALLOGRAFT TRANSPLANTATION
12.3 AUTOLOGOUS CHONDROCYTE IMPLANTATION
12.4 MATRIX AUTOLOGOUS CARTILAGE IMPLANTATION (MACI)
12.5 CHONDROPLASTY AND MICROFRACTURE
12.6 OSTEOTOMY
12.7 ARTHROSCOPY
12.8 ABRASION ARTHROPLASTY
12.9 JUVENILE ALLOGRAFT FRAGMENTS
12.1 OTHERS
13 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS AND CLINICS
13.2.1 PRIVATE
13.2.2 PUBLIC
13.3 ACADEMIC AND RESEARCH INSTITUTES
13.4 AMBULATORY SURGICAL CENTERS
13.5 ORTHOCENTERS
13.6 OTHERS
14 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY REGION
14.1 U.S.
14.2 EUROPE
14.2.1 GERMANY
14.2.2 U.K.
14.2.3 FRANCE
14.2.4 ITALY
14.2.5 SPAIN
14.2.6 RUSSIA
14.2.7 POLAND
14.2.8 SWITZERLAND
14.2.9 NETHERLANDS
14.2.10 TURKEY
14.2.11 SWEDEN
14.2.12 BELGIUM
14.2.13 DENMARK
14.2.14 FINLAND
14.2.15 NORWAY
14.2.16 REST OF EUROPE
15 U.S. CARTILAGE REGENERATION MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: U.S.
15.2 COMPANY SHARE ANALYSIS: EUROPE
16 COMPANY PROFILE
16.1 ZIMMER BIOMET
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 VERICEL CORPORATION.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 ARTHREX, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 PRODUCT PORTFOLIO
16.3.3 RECENT DEVELOPMENT
16.4 CONMED
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 RTI SURGICAL
16.5.1 COMPANY SNAPSHOT
16.5.2 PRODUCT PORTFOLIO
16.5.3 RECENT DEVELOPMENT
16.6 ALLOSOURCE
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 ANIKA THERAPEUTICS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 1.4.4 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 BIOINOVA, A.S.
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 CARTILAGE INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 CO.DON
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 GEISTLICH PHARMA AG
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 HISTOGEN INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 LAMINA THERAPEUTICS
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 MEIDRIX BIOMEDICALS GMBH
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 NOVARTIS AG
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 SMITH & NEPHEW
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 TETEC AG
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 U.S. NUMBER OF PROCEDURES PER YEAR
TABLE 2 GERMANY NUMBER OF PROCEDURES PER YEAR
TABLE 3 U.K. NUMBER OF PROCEDURES PER YEAR
TABLE 4 FRANCE NUMBER OF PROCEDURES PER YEAR
TABLE 5 ITALY NUMBER OF PROCEDURES PER YEAR
TABLE 6 SPAIN NUMBER OF PROCEDURES PER YEAR
TABLE 7 RUSSIA NUMBER OF PROCEDURES PER YEAR
TABLE 8 POLAND NUMBER OF PROCEDURES PER YEAR
TABLE 9 SWITZERLAND NUMBER OF PROCEDURES PER YEAR
TABLE 10 NETHERLANDS NUMBER OF PROCEDURES PER YEAR
TABLE 11 TURKEY NUMBER OF PROCEDURES PER YEAR
TABLE 12 SWEDEN NUMBER OF PROCEDURES PER YEAR
TABLE 13 BELGIUM NUMBER OF PROCEDURES PER YEAR
TABLE 14 DENMARK NUMBER OF PROCEDURES PER YEAR
TABLE 15 FINLAND NUMBER OF PROCEDURES PER YEAR
TABLE 16 NORWAY NUMBER OF PROCEDURES PER YEAR
TABLE 17 COST OF PROCEDURES
TABLE 18 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 U.S. & EUROPE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 20 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 21 U.S. & EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 22 U.S. & EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 23 U.S. & EUROPE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 24 U.S. & EUROPE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 25 U.S. & EUROPE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 26 U.S. & EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 27 U.S. & EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 28 U.S. & EUROPE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 U.S. & EUROPE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 30 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 U.S. & EUROPE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 32 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 33 U.S. & EUROPE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 34 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 35 U.S. & EUROPE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 36 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 37 U.S. & EUROPE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 U.S. CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 39 U.S. FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 40 U.S. CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 41 U.S. CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 42 U.S. CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 43 U.S. STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 44 U.S. GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 45 U.S. NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 46 U.S. SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 47 U.S. NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 U.S. SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 49 U.S. CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 50 U.S. CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 U.S. PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 U.S. CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 53 U.S. KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 U.S. CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 55 U.S. OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 U.S. CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 57 U.S. HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 EUROPE CARTILAGE REGENERATION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 59 EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 60 EUROPE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 61 EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 62 EUROPE CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 63 EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 64 EUROPE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 65 EUROPE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 66 EUROPE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 67 EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 68 EUROPE NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 EUROPE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 EUROPE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 71 EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 EUROPE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 73 EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 74 EUROPE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 76 EUROPE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 EUROPE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 78 EUROPE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 GERMANY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 GERMANY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 81 GERMANY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 82 GERMANY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 83 GERMANY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 84 GERMANY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 85 GERMANY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 86 GERMANY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 87 GERMANY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 88 GERMANY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 GERMANY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 GERMANY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 91 GERMANY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 GERMANY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 GERMANY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 94 GERMANY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 95 GERMANY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 96 GERMANY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 GERMANY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 98 GERMANY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 U.K. CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 U.K. FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 101 U.K. CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 102 U.K. CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 103 U.K. CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 104 U.K. STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 105 U.K. GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 106 U.K. NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 107 U.K. SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 108 U.K. NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 109 U.K. SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 U.K. CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 111 U.K. CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 U.K. PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 U.K. CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 114 U.K. KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 115 U.K. CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 116 U.K. OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 U.K. CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 118 U.K. HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 119 FRANCE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 120 FRANCE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 121 FRANCE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 122 FRANCE CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 123 FRANCE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 124 FRANCE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 125 FRANCE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 126 FRANCE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 127 FRANCE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 128 FRANCE NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 129 FRANCE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 FRANCE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 131 FRANCE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 FRANCE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 FRANCE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 134 FRANCE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 FRANCE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 136 FRANCE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 FRANCE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 138 FRANCE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 ITALY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 ITALY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 ITALY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 142 ITALY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 143 ITALY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 144 ITALY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 145 ITALY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 146 ITALY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 147 ITALY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 148 ITALY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 ITALY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 ITALY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 151 ITALY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 ITALY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 ITALY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 154 ITALY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 155 ITALY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 156 ITALY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 ITALY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 158 ITALY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 SPAIN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 SPAIN FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 SPAIN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 162 SPAIN CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 163 SPAIN CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 164 SPAIN STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 165 SPAIN GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 166 SPAIN NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 167 SPAIN SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 168 SPAIN NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 169 SPAIN SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 170 SPAIN CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 171 SPAIN CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 SPAIN PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 SPAIN CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 174 SPAIN KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 175 SPAIN CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 176 SPAIN OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 177 SPAIN CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 178 SPAIN HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 RUSSIA CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 180 RUSSIA FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 RUSSIA CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 182 RUSSIA CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 183 RUSSIA CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 184 RUSSIA STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 185 RUSSIA GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 186 RUSSIA NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 187 RUSSIA SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 188 RUSSIA NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 189 RUSSIA SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 190 RUSSIA CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 191 RUSSIA CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 RUSSIA PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 193 RUSSIA CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 194 RUSSIA KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 RUSSIA CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 196 RUSSIA OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 197 RUSSIA CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 198 RUSSIA HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 POLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 200 POLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 201 POLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 202 POLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 203 POLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 204 POLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 205 POLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 206 POLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 207 POLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 208 POLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 209 POLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 210 POLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 211 POLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 212 POLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 POLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 214 POLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 215 POLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 216 POLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 217 POLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 218 POLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 SWITZERLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 221 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 222 SWITZERLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 223 SWITZERLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 224 SWITZERLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 225 SWITZERLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 226 SWITZERLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 227 SWITZERLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 228 SWITZERLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 SWITZERLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 230 SWITZERLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 231 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 232 SWITZERLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 SWITZERLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 234 SWITZERLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 235 SWITZERLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 236 SWITZERLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 SWITZERLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 238 SWITZERLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 240 NETHERLANDS FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 241 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 242 NETHERLANDS CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 243 NETHERLANDS CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 244 NETHERLANDS STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 245 NETHERLANDS GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 246 NETHERLANDS NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 247 NETHERLANDS SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 248 NETHERLANDS NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 249 NETHERLANDS SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 250 NETHERLANDS CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 251 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 252 NETHERLANDS PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 NETHERLANDS CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 254 NETHERLANDS KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 255 NETHERLANDS CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 256 NETHERLANDS OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 NETHERLANDS CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 258 NETHERLANDS HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 259 TURKEY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 260 TURKEY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 TURKEY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 262 TURKEY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 263 TURKEY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 264 TURKEY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 265 TURKEY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 266 TURKEY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 267 TURKEY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 268 TURKEY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 269 TURKEY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 270 TURKEY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 271 TURKEY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 272 TURKEY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 TURKEY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 274 TURKEY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 275 TURKEY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 276 TURKEY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 TURKEY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 278 TURKEY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 SWEDEN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 280 SWEDEN FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 281 SWEDEN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 282 SWEDEN CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 283 SWEDEN CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 284 SWEDEN STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 285 SWEDEN GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 286 SWEDEN NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 287 SWEDEN SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 288 SWEDEN NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 289 SWEDEN SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 290 SWEDEN CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 291 SWEDEN CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 292 SWEDEN PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 293 SWEDEN CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 294 SWEDEN KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 295 SWEDEN CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 296 SWEDEN OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 297 SWEDEN CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 298 SWEDEN HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 299 BELGIUM CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 300 BELGIUM FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 BELGIUM CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 302 BELGIUM CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 303 BELGIUM CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 304 BELGIUM STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 305 BELGIUM GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 306 BELGIUM NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 307 BELGIUM SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 308 BELGIUM NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 309 BELGIUM SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 310 BELGIUM CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 311 BELGIUM CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 312 BELGIUM PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 313 BELGIUM CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 314 BELGIUM KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 315 BELGIUM CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 316 BELGIUM OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 317 BELGIUM CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 318 BELGIUM HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 319 DENMARK CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 320 DENMARK FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 321 DENMARK CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 322 DENMARK CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 323 DENMARK CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 324 DENMARK STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 325 DENMARK GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 326 DENMARK NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 327 DENMARK SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 328 DENMARK NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 329 DENMARK SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 330 DENMARK CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 331 DENMARK CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 332 DENMARK PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 DENMARK CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 334 DENMARK KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 335 DENMARK CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 336 DENMARK OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 337 DENMARK CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 338 DENMARK HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 339 FINLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 340 FINLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 341 FINLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 342 FINLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 343 FINLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 344 FINLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 345 FINLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 346 FINLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 347 FINLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 348 FINLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 349 FINLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 350 FINLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 351 FINLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 352 FINLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 353 FINLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 354 FINLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 355 FINLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 356 FINLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 357 FINLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 358 FINLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 NORWAY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 360 NORWAY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 361 NORWAY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 362 NORWAY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 363 NORWAY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 364 NORWAY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 365 NORWAY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 366 NORWAY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 367 NORWAY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 368 NORWAY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 369 NORWAY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 370 NORWAY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 371 NORWAY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 372 NORWAY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 373 NORWAY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 374 NORWAY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 375 NORWAY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 376 NORWAY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 377 NORWAY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 378 NORWAY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 379 REST OF EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
图片列表
FIGURE 1 U.S. & EU CARTILAGE REGENERATION MARKET: SEGMENTATION
FIGURE 2 U.S. & EU CARTILAGE REGENERATION MARKET: DATA TRIANGULATION
FIGURE 3 U.S. & EU CARTILAGE REGENERATION MARKET: DROC ANALYSIS
FIGURE 4 U.S. & EU CARTILAGE REGENERATION MARKET: REGIONAL VS COUNTRYMARKET ANALYSIS
FIGURE 5 U.S. & EU CARTILAGE REGENERATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. & EU CARTILAGE REGENERATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. & EU CARTILAGE REGENERATION MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 U.S. & EU CARTILAGE REGENERATION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 U.S. & EU CARTILAGE REGENERATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 U.S. & EU CARTILAGE REGENERATION MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF OSTEOARTHRITIS AND RISING HEALTHCARE EXPENDITURE ARE DRIVING THE GROWTH OF THE U.S. & EU CARTILAGE REGENERATION MARKET FROM 2024 TO 2034
FIGURE 12 HYALINE CARTILAGE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. AND EU CARTILAGE REGENERATION MARKET IN 2024 TO 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE U.S. & EU CARTILAGE REGENERATION MARKET
FIGURE 14 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, 2023
FIGURE 15 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 16 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, CAGR (2024-2031)
FIGURE 17 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, LIFELINE CURVE
FIGURE 18 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, 2022
FIGURE 19 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, 2024-2031 (USD THOUSAND)
FIGURE 20 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, CAGR (2024-2031)
FIGURE 21 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, LIFELINE CURVE
FIGURE 22 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, 2022
FIGURE 23 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 24 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, CAGR (2024-2031)
FIGURE 25 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 26 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, 2023
FIGURE 27 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, 2024-2031 (USD THOUSAND)
FIGURE 28 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, CAGR (2024-2031)
FIGURE 29 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, LIFELINE CURVE
FIGURE 30 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE , 2023
FIGURE 31 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE , 2024-2031 (USD THOUSAND)
FIGURE 32 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE, CAGR (2024-2031)
FIGURE 33 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE, LIFELINE CURVE
FIGURE 34 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, 2023
FIGURE 35 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 36 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, CAGR (2024-2031)
FIGURE 37 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE CARTILAGE REGENERATION MARKET: SNAPSHOT (2023)
FIGURE 39 U.S. CARTILAGE REGENERATION MARKET: COMPANY SHARE 2023 (%)
FIGURE 40 EUROPE CARTILAGE REGENERATION MARKET: COMPANY SHARE 2023 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
